Prelude Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Prelude Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.06M	Hold	52,578	–	–	0.16%	163
2025 Q4	$810K	Buy	+52,578	New	+$1.05M	0.06%	371
2024 Q2	–	Sell	-12,484	Closed	-$220K	–	1302
2024 Q1	$220K	Buy	+12,484	New	+$192K	0.02%	1061
2023 Q3	–	Sell	-33,550	Closed	-$26.8K	–	1200
2023 Q2	$26.8K	Sell	33,550 -512	-2%	-$10.3K	﹤0.01%	1004
2023 Q1	$40K	Buy	34,062 +18,776	+123%	+$382K	﹤0.01%	1014
2022 Q4	$250K	Buy	+15,286	New	+$244K	0.02%	878
2022 Q2	–	Sell	-4,886	Closed	-$37K	–	1901
2022 Q1	$37K	Buy	4,886 +175	+4%	+$1.15K	﹤0.01%	1506
2021 Q4	$42K	Buy	+4,711	New	+$61.8K	﹤0.01%	1792
2020 Q2	–	Sell	-476	Closed	-$31K	–	2082
2020 Q1	$31K	Buy	+476	New	+$30.3K	0.01%	873

Other funds holding ELVN

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return